journal article·2021-03Open access

Effect of pore size and spacing on neovascularization of a biodegradble shape memory polymer perivascular wrap

Timothy C. Boire, Lauren E. Himmel, Fang Yu, Christy M. Guth, Bryan R. Dollinger, Thomas A. Werfel, Daniel A. Balikov, Craig L. Duvall

Abstract

Abstract Neointimal hyperplasia (NH) is a main source of failures in arteriovenous fistulas and vascular grafts. Several studies have demonstrated the promise of perivascular wraps to reduce NH via promotion of adventitial neovascularization and providing mechanical support. Limited clinical success thus far may be due to inappropriate material selection (e.g., nondegradable, too stiff) and geometric design (e.g., pore size and spacing, diameter). The influence of pore size and spacing on implant neovascularization is investigated here for a new biodegradable, thermoresponsive shape memory polymer (SMP) perivascular wrap. Following an initial pilot, 21 mice were each implanted with six scaffolds: four candidate SMP macroporous designs (a–d), a nonporous SMP control (e), and microporous GORETEX (f). Mice were sacrificed after 4 (N = 5), 14 (N = 8), and 28 (N = 8) days. There was a statistically significant increase in neovascularization score between all macroporous groups compared to nonporous SMP (p < .023) and microporous GORETEX (p < .007) controls at Day 28. Wider‐spaced, smaller‐sized pore designs (223 μm‐spaced, 640 μm‐diameter Design c) induced the most robust angiogenic response, with greater microvessel number (p < .0114) and area (p < .0055) than nonporous SMPs and GORETEX at Day 28. This design also produced significantly greater microvessel density than nonporous SMPs (p = 0.0028) and a smaller‐spaced, larger‐sized pore (155 μm‐spaced, 1,180 μm‐sized Design b) design (p = .0013). Strong neovascularization is expected to reduce NH, motivating further investigation of this SMP wrap with controlled pore spacing and size in more advanced arteriovenous models.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Vascular Malformations Diagnosis and Treatment · Infectious Aortic and Vascular Conditions · Intracranial Aneurysms: Treatment and Complications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering Vanderbilt University Nashville Tennessee USA

Department of Mechanical Engineering Vanderbilt University Nashville Tennessee USA

Department of Pathology, Microbiology and Immunology Vanderbilt University Medical Center Nashville Tennessee USA

Department of Surgery Vanderbilt University Medical Center Nashville Tennessee USA

Biomedical Engineering Program University of Mississippi Oxford Mississippi USA

Funding

American Heart Association · Foundation for the National Institutes of Health · National Cancer Institute · National Center for Advancing Translational Sciences · National Science Foundation

References (90)

Show source-provided references
1. 10.1016/0741-5214(87)90148-010.1016/0741-5214(87)90148-0 ↗
2. 10.1001/jama.294.19.244610.1001/jama.294.19.2446 ↗
3. 10.1053/j.ajkd.2013.08.02310.1053/j.ajkd.2013.08.023 ↗
4. 10.1016/j.smim.2007.11.00410.1016/j.smim.2007.11.004 ↗
5. 10.1016/S0022-5223(96)70180-010.1016/S0022-5223(96)70180-0 ↗
6. 10.1074/jbc.M00242320010.1074/jbc.M002423200 ↗
7. 10.1053/j.ajkd.2007.09.01210.1053/j.ajkd.2007.09.012 ↗
8. 10.1089/ten.tea.2007.026410.1089/ten.tea.2007.0264 ↗
9. 10.1016/S0197-3975(97)00111-510.1016/S0197-3975(97)00111-5 ↗
10. 10.1038/s41598-017-17204-510.1038/s41598-017-17204-5 ↗
11. 10.1002/marc.20160041210.1002/marc.201600412 ↗
12. 10.1016/j.actbio.2015.06.00410.1016/j.actbio.2015.06.004 ↗
13. Long‐term fate of bypass grafts: The coronary artery surgery study (CASS) and Montreal Heart Institute experiences
14. 10.1016/j.actbio.2011.11.03110.1016/j.actbio.2011.11.031 ↗
15. 10.1016/S0967-2109(00)00104-610.1016/S0967-2109(00)00104-6 ↗
16. Local application of recombinant human type I pancreatic elastase (PRT‐201) to an arteriovenous fistula (AVF) increases AVF blood flow in a rabbit model
17. Recombinant human elastase (PRT‐201) dilates outflow veins in a rabbit mode of arteriovenous fistula
18. Recombinant human pancreatic elastase (prt‐201) dilates the arteriovenous graft (AVG) outflow vein and increases graft blood flow in a porcine femoral AVG model
19. 10.1038/3502522010.1038/35025220 ↗
20. 10.1152/ajpheart.00411.201110.1152/ajpheart.00411.2011 ↗
21. 10.1056/NEJM19840126310040110.1056/NEJM198401263100401 ↗
22. 10.1093/nar/gky104910.1093/nar/gky1049 ↗
23. 10.1016/j.jvs.2007.02.03110.1016/j.jvs.2007.02.031 ↗
24. 10.1016/j.jvs.2005.12.05810.1016/j.jvs.2005.12.058 ↗
25. 10.1016/j.jvs.2009.07.10810.1016/j.jvs.2009.07.108 ↗
26. 10.1074/mcp.M113.03159110.1074/mcp.M113.031591 ↗
27. 10.1007/s13239-017-0307-010.1007/s13239-017-0307-0 ↗
28. 10.1016/j.jamcollsurg.2011.01.00610.1016/j.jamcollsurg.2011.01.006 ↗
29. 10.1056/NEJMoa080584010.1056/NEJMoa0805840 ↗
30. 10.1016/0741-5214(87)90034-610.1016/0741-5214(87)90034-6 ↗
31. 10.1021/acsnano.5b0049110.1021/acsnano.5b00491 ↗
32. 10.1126/scitranslmed.aaa454910.1126/scitranslmed.aaa4549 ↗
33. 10.1016/0735-1097(96)00206-910.1016/0735-1097(96)00206-9 ↗
34. Franano F. N. · 2007 · 155
35. Clinical protocol. A phase IIb, randomized, multicenter, double‐blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft‐vein anastomosis site in dialysis patients
36. 10.1016/S0021-9150(00)00588-810.1016/S0021-9150(00)00588-8 ↗
37. 10.1161/01.CIR.89.3.113810.1161/01.CIR.89.3.1138 ↗
38. 10.1007/s10029-007-0276-610.1007/s10029-007-0276-6 ↗
39. 10.1007/s10047-003-0232-x10.1007/s10047-003-0232-x ↗
40. 10.1016/S0741-5214(03)00426-910.1016/S0741-5214(03)00426-9 ↗
41. 10.1016/j.jvs.2014.02.03710.1016/j.jvs.2014.02.037 ↗
42. 10.1016/j.jtcvs.2003.09.05410.1016/j.jtcvs.2003.09.054 ↗
43. 10.1016/j.biomaterials.2006.10.02310.1016/j.biomaterials.2006.10.023 ↗
44. 10.1002/jbm.b.3456110.1002/jbm.b.34561 ↗
45. 10.1016/j.biomaterials.2005.02.00210.1016/j.biomaterials.2005.02.002 ↗
46. 10.1097/00000658-197802000-0001610.1097/00000658-197802000-00016 ↗
47. 10.1016/j.msec.2013.02.01610.1016/j.msec.2013.02.016 ↗
48. 10.7181/acfs.2014.15.2.8210.7181/acfs.2014.15.2.82 ↗
49. 10.1007/s10029-012-0913-610.1007/s10029-012-0913-6 ↗
50. 10.1002/jbm.b.3295810.1002/jbm.b.32958 ↗
51. 10.1055/s-2003-4136510.1055/s-2003-41365 ↗
52. Candida albicans biofilm development on medically‐relevant foreign bodies in a mouse subcutaneous model followed by bioluminescence imaging
53. 10.1016/j.jmbbm.2014.11.01110.1016/j.jmbbm.2014.11.011 ↗
54. 10.1016/j.clindermatol.2006.09.00710.1016/j.clindermatol.2006.09.007 ↗
55. 10.1038/ki.2008.31810.1038/ki.2008.318 ↗
56. 10.1111/j.1755-5922.2010.00207.x10.1111/j.1755-5922.2010.00207.x ↗
57. 10.2215/CJN.0073011210.2215/CJN.00730112 ↗
58. Arteriovenous access failure, stenosis, and thrombosis10.1177/2054358116669126 ↗
59. 10.1038/nm.350810.1038/nm.3508 ↗
60. 10.1053/j.otsm.2004.07.01510.1053/j.otsm.2004.07.015 ↗
61. 10.1111/j.1445-2197.1989.tb01466.x10.1111/j.1445-2197.1989.tb01466.x ↗
62. 10.1038/nm0298-23510.1038/nm0298-235 ↗
63. 10.1016/j.jvir.2010.02.03010.1016/j.jvir.2010.02.030 ↗
64. 10.1007/s00011-004-1319-410.1007/s00011-004-1319-4 ↗
65. 10.1001/archsurg.1992.0142004005801010.1001/archsurg.1992.01420040058010 ↗
66. 10.1253/circj.CJ-10-049510.1253/circj.CJ-10-0495 ↗
67. 10.1016/0741-5214(89)90217-610.1016/0741-5214(89)90217-6 ↗
68. 10.1016/B978-0-323-08697-4.00008-310.1016/B978-0-323-08697-4.00008-3 ↗
69. 10.1016/j.jvs.2016.08.10110.1016/j.jvs.2016.08.101 ↗
70. 10.1042/BST035118710.1042/BST0351187 ↗
71. 10.1073/pnas.090676110610.1073/pnas.0906761106 ↗
72. 10.1016/j.coph.2009.11.00510.1016/j.coph.2009.11.005 ↗
73. 10.1002/jbm.a.3238110.1002/jbm.a.32381 ↗
74. 10.1681/ASN.200505061510.1681/ASN.2005050615 ↗
75. 10.1111/j.1582-4934.2005.tb00355.x10.1111/j.1582-4934.2005.tb00355.x ↗
76. 10.1016/j.athoracsur.2004.07.04710.1016/j.athoracsur.2004.07.047 ↗
77. 10.1161/CIRCULATIONAHA.111.03984210.1161/CIRCULATIONAHA.111.039842 ↗
78. 10.1093/ndt/14.1.11810.1093/ndt/14.1.118 ↗
79. 10.1016/j.biomaterials.2014.02.01210.1016/j.biomaterials.2014.02.012 ↗
80. 10.1172/JCI687010.1172/JCI6870 ↗
81. 10.1016/0021-9290(92)90027-X10.1016/0021-9290(92)90027-X ↗
82. System USRD · 2018
83. 10.1016/S1078-5884(05)80163-710.1016/S1078-5884(05)80163-7 ↗
84. 10.1016/j.jvs.2004.08.04710.1016/j.jvs.2004.08.047 ↗
85. 10.1016/j.matbio.2015.01.01610.1016/j.matbio.2015.01.016 ↗
86. 10.1186/s41100-016-0021-710.1186/s41100-016-0021-7 ↗
87. 10.4172/2329-6607.100017810.4172/2329-6607.1000178 ↗
88. 10.1038/srep3093310.1038/srep30933 ↗
89. 10.1016/S0142-9612(03)00478-210.1016/S0142-9612(03)00478-2 ↗
90. 10.4240/wjgs.v7.i10.22610.4240/wjgs.v7.i10.226 ↗